Featured Trials

Not all clinical trials are the same. That’s why our review team of patients and researchers helped to identify trials we believe are going above and beyond for patients and families; our Featured Trials. For your safety and to protect your rights, these and all other clinical trials are reviewed by an Institutional Review Board (IRB).

Researchers

Just like you, we believe in a better tomorrow where everyone finds the cure they desperately seek. Is there a clinical trial you'd like to see featured on the CTSS website?

Apply Here

Patients & Caregivers

Every day, we strive to lead with clarity to keep overwhelm at bay. Do you have questions that need answers? Would you like to participate in a featured trial?

A drug, odronextamab, in combination with lenalidomide, to treat follicular lymphoma and marginal zone lymphoma (MZL) that has come back (relapsed) or not gotten better with treatment (refractory)
To find out if the combination of odronextamab and lenalidomide is safe and works well to treat follicular lymphoma and MZL that has relapsed or is refractory

Welcome to the Jason Carter Clinical Trials Website

Featured Trials

Researchers

Patients & Caregivers

A drug, odronextamab, in combination with lenalidomide, to treat follicular lymphoma and marginal zone lymphoma (MZL) that has come back (relapsed) or not gotten better with treatment (refractory)